| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.21 | 0.2 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | -0.23 | 0.3 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.046 | 0.3 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.058 | 0.3 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |